Observational studyBMC infectious diseases2026
Clinical characteristics and mortality of critically ill patients with chikungunya infection: a multicenter study in Paraguay.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChikungunya virus (CHIKV) infection can progress to severe clinical forms requiring intensive care. This study aimed to characterize adult patients admitted to intensive care units (ICUs) with CHIKV during the 2023 epidemic in five hospitals in the Central Department of Paraguay. It also sought to estimate mortality and explore clinical and biochemical factors linked to poor outcomes to facilitate early identification of high-risk patients and guide targeted therapies.
methodsA multicenter retrospective observational cohort study with an analytical component was conducted through a retrospective review of medical records. Adult patients admitted to the ICU of four hospitals between January and June 2023 were included if they had confirmed CHIKV infection (RT-PCR or serology) requiring intensive care. The data collected included demographics, comorbidities, clinical presentation, laboratory findings, interventions (mechanical ventilation, vasopressors, renal replacement therapy), ICU stay, and mortality. APACHE II and SOFA scores were calculated at the time of UCI admission.
resultsThirty-four patients were included, with a median age of 66 years (range 22–89), predominantly male (55.9%). Hypertension (64.7%) and obesity (35.3%) were the most frequent comorbidities. The most common presenting symptoms were fever (82.4%), gastrointestinal manifestations (76.5%), asthenia or anorexia (70.6%), and neurological symptoms (58.8%). The median APACHE II and SOFA scores on ICU admission were 19 and 7, respectively. Mechanical ventilation and vasopressors support were required in 79.4% of patients, while renal replacement therapy was needed in 32.4%. Overall mortality was 55.9%. Atypical presentations occurred in 88.2% of cases, predominantly with renal (36.7%) and neurological (33.3%) involvement. Higher APACHE II and SOFA scores, as well as the need for mechanical ventilation, vasopressors, and renal therapy were significantly associated with mortality.
conclusionsThis first description of severe CHIKV infection in Paraguay highlights extensive multiorgan involvement, a high requirement for advanced life support use, and elevated mortality associated with the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.